Cas9 Stable Cell Line - H22

The H22 cell line, derived from mouse hepatocellular carcinoma, is widely used in oncology and immunology research due to its potent tumorigenicity in homogeneous mouse models. The Cas9 Stable Cell Line - H22 was constructed by integrating the CRISPR-associated protein 9 (Cas9) gene into the H22 genome, thereby achieving stable constitutive expression of the Cas9 endonuclease. This modification allows researchers to overcome the problem of low transient transfection efficiency, ensuring consistent gene editing efficiency across different experiments. This cell line has been validated to possess high Cas9 activity, minimal off-target effects, and compatibility with sgRNA delivery systems. The model retains characteristics of parental H22 cells, such as rapid proliferation and epithelial morphology, making it ideal for reproducible gene manipulation.

The Cas9 Stable Cell Line - H22 has revolutionized functional genomics and drug development by enabling precise, high-throughput genome editing. Researchers utilize this tool for targeted gene knockout to investigate tumor suppressor genes, oncogenes, and signaling pathways in hepatocellular carcinoma progression, metastasis, and drug resistance. It facilitates CRISPR screening using sgRNA libraries to identify novel therapeutic targets or genetic modifiers of chemotherapy responses. In immunotherapy research, this cell line helps build models of immune checkpoint interactions (e.g., PD-1/PD-L1) by editing immune regulatory genes. Furthermore, it supports in vivo applications: implantation into mice allows for the creation of customizable tumor models to assess gene function in the tumor microenvironment or test CRISPR-based therapies. Beyond cancer research, it simplifies mechanistic studies in areas such as liver metabolism, viral infections (e.g., HBV), and regenerative medicine, accelerating translational research.